Diabetes News October 22nd 2010

The Older Patient: bridging the gap between primary and secondary care
The symposium will focus on clinical advances in elderly medicine and the role of primary and secondary care – Agenda. The full day conference will be held on Wednesday October 27th at the Royal Society of Medicine, London. (Geriatric Medicine)

Annual Professional Conference 2011
One step ahead: meeting future challenges in diabetes. 30 March-1 April 2011 International Convention Centre (ICC) London ExCeL. Programme (Diabetes UK)

Road Map for diabetes research in Europe
PDF files are now available for download. The mission of DIAMAP is to undertake a wide survey of the current European diabetes research landscape, from which expert opinion can identify gaps and highlight strengths, to guide a Road Map strategy for diabetes research in Europe (DIAMAP)

Diabetes and Chronic Liver Disease: Etiology and Pitfalls in Monitoring
Because A1C is currently being used as both a diagnostic test and a parameter of good practice in monitoring glucose control in diabetic patients, it is easy to overlook the fact that its relationship with blood glucose has been established in patients without anemia, chronic kidney or liver disease, or therapies that can interfere with results (Clinical Diabetes)

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations
These data will assist recommending appropriate length needles for subcutaneous insulin injections in adults (Current Medical Research & Opinion)

Comparative glycemic control, safety and patient ratings for a new 4 mm\32G insulin pen needle in adults with diabetes
The 4 mm x 32G PN provided equivalent glycemic control compared to 31G, 5 mm and 8 mm PNs with reduced pain, no difference in insulin leakage and was preferred by patients (Current Medical Research & Opinion)

Early clinical studies with liraglutide
The promising results achieved during preclinical development of liraglutide have been reinforced during Phase 1 and 2 clinical testing. This encouraging body of early studies, which determined the pharmacokinetic/pharmacodynamic profile of liraglutide and defined optimal dosing, supported liraglutide as an effective and well-tolerated candidate for a comprehensive Phase 3 clinical development programme (International Journal of Clinical Practice)

Diabetes Treatment: Insulin and Incretins
Although injected medications such as GLP-1 agonists, insulin, and insulin analogs are viewed with trepidation among many patients, their effectiveness merits their use in clinical medicine (Clinical Diabetes)

Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine
Patients with uncontrolled type 2 diabetes have severely deficient synthesis of glutathione due to limited precursor availability. Dietary supplementation with GSH precursor amino-acids can restore GSH synthesis and lower oxidative stress and oxidant damage in the face of persistent hyperglycemia (Diabetes Care)

GI Dynamics Receives European CE Mark Approval for 12 Months of EndoBarrier™ Treatment of Type 2 Diabetes and Obesity
This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom (GI Dynamics)

Enterovirus RNA in Blood Is Linked to the Development of Type 1 Diabetes
The present study supports the hypothesis that enteroviruses play a role in the pathogenesis of type 1 diabetes, especially in the initiation of the ß-cell damaging process. The enterovirus-associated risk for type 1 diabetes may be stronger in boys than in girls (Diabetes)

FDA Rejects Amylin/Lilly’s Once-Weekly Exenatide for Diabetes
The U.S. Food and Drug Administration (FDA) has rejected Amylin and Eli Lilly’s extended–release exenatide (Bydureon)‚ a long–acting‚ once–weekly version of the diabetes drug Byetta (American Diabetes Association)

Reduction in the Incidence of Type 2-Diabetes with the Mediterranean Diet: Results of the PREDIMED-Reus Nutrition Intervention Randomized Trial
Mediterranean diets without calorie restriction appear to be effective in the prevention of diabetes in subjects at high cardiovascular risk (Diabetes Care)